Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Grants Fast Track Designation to Cesalatamig in Immunotherapy-Pretreated NSCLC

16 September 2026 · By · Wire by Fusion42

Published

16 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 17 September 2026 · Fusion42 review

The FDA has granted Fast Track designation to Cesalatamig for treating patients with non-small cell lung cancer (NSCLC) who have previously received immunotherapy, expediting the development and review process for this drug candidate.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 16 Sep 2026 and 17 Sep 2026.

◆ ◆ The Wire takeaway

FDA's move speeds up potential market entry for immunotherapy in NSCLC. Biotech founders developing cancer treatments should accelerate clinical plans to leverage faster review timings.

◆ Coverage

2 sources · first reported 16 Sep 2026 · latest 17 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfdafast-trackoncologynsclcdrug-development